Mutual Termination Agreement between PharmaCyte Biotech, Inc. and Chardan Capital Markets, LLC
PharmaCyte Biotech, Inc. and Chardan Capital Markets, LLC have agreed to mutually end their previous engagement agreement, originally signed in 2014 and amended in 2016. Both parties confirm that no further fees or warrants are owed by PharmaCyte to Chardan. This agreement is effective as of January 26, 2018, and is acknowledged by both companies' representatives.
Exhibit 10.2
VIA EMAIL ONLY
January 26, 2018
Kerry Propper
Chief Executive Officer
Chardan Capital Markets, LLC
17 State Street
New York, NY 10004
Re: Mutual Termination Agreement
Dear Mr. Propper:
This letter is to confirm that PharmaCyte Biotech, Inc. (“Company”) and Chardan Capital Markets, LLC (“Chardan”) have agreed to mutually terminate the letter agreement between Chardan Capital Markets, LLC (“Chardan”) and the Company dated May 28, 2014, as amended on December 15, 2016 (collectively, “Engagement Agreement”). Chardan agrees that no further fees or warrants are due and payable by the Company to Chardan pursuant to the Engagement Agreement.
| Sincerely, | |
| /s/ Kenneth L. Waggoner | |
| Chief Executive Officer | |
| President and General Cousel | |
Acknowledged and Agreed
Chardan Capital Markets, LLC
By: /s/ George Kaufman
Name: George Kaufman
Title: Managing Director
